Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) EBITDA (2019 - 2025)

Cyclerion Therapeutics (CYCN) has 7 years of EBITDA data on record, last reported at -$976000.0 in Q3 2025.

  • For Q3 2025, EBITDA fell 34.99% year-over-year to -$976000.0; the TTM value through Sep 2025 reached -$3.6 million, up 33.13%, while the annual FY2024 figure was -$3.6 million, 71.99% up from the prior year.
  • EBITDA reached -$976000.0 in Q3 2025 per CYCN's latest filing, up from -$1.7 million in the prior quarter.
  • Across five years, EBITDA topped out at $12.4 million in Q4 2022 and bottomed at -$16.2 million in Q2 2021.
  • Average EBITDA over 5 years is -$5.3 million, with a median of -$4.2 million recorded in 2023.
  • Peak YoY movement for EBITDA: skyrocketed 186.44% in 2022, then tumbled 114.48% in 2023.
  • A 5-year view of EBITDA shows it stood at -$14.3 million in 2021, then surged by 186.44% to $12.4 million in 2022, then crashed by 114.48% to -$1.8 million in 2023, then skyrocketed by 127.97% to $502000.0 in 2024, then crashed by 294.42% to -$976000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$976000.0 in Q3 2025, -$1.7 million in Q2 2025, and -$1.5 million in Q1 2025.